PL3664894T3 - Saccharomyces boulardii w leczeniu zaburzeń nastroju - Google Patents

Saccharomyces boulardii w leczeniu zaburzeń nastroju

Info

Publication number
PL3664894T3
PL3664894T3 PL18762232T PL18762232T PL3664894T3 PL 3664894 T3 PL3664894 T3 PL 3664894T3 PL 18762232 T PL18762232 T PL 18762232T PL 18762232 T PL18762232 T PL 18762232T PL 3664894 T3 PL3664894 T3 PL 3664894T3
Authority
PL
Poland
Prior art keywords
treatment
mood disorders
saccharomyces boulardii
boulardii
saccharomyces
Prior art date
Application number
PL18762232T
Other languages
English (en)
Inventor
Emmanuelle SIMON O'BRIEN
Marc Verleye
Marie-Emmanuelle Le Guern
Original Assignee
Biocodex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59745858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3664894(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocodex filed Critical Biocodex
Publication of PL3664894T3 publication Critical patent/PL3664894T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18762232T 2017-08-11 2018-08-10 Saccharomyces boulardii w leczeniu zaburzeń nastroju PL3664894T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306065 2017-08-11
PCT/EP2018/071726 WO2019030371A1 (fr) 2017-08-11 2018-08-10 Saccharomyces boulardii pour le traitement des troubles de l'humeur
EP18762232.9A EP3664894B1 (fr) 2017-08-11 2018-08-10 Saccharomyces boulardii pour le traitement des troubles de l'humeur

Publications (1)

Publication Number Publication Date
PL3664894T3 true PL3664894T3 (pl) 2022-02-14

Family

ID=59745858

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18762232T PL3664894T3 (pl) 2017-08-11 2018-08-10 Saccharomyces boulardii w leczeniu zaburzeń nastroju

Country Status (7)

Country Link
US (1) US11872257B2 (pl)
EP (1) EP3664894B1 (pl)
CA (1) CA3072544A1 (pl)
ES (1) ES2900380T3 (pl)
PL (1) PL3664894T3 (pl)
PT (1) PT3664894T (pl)
WO (1) WO2019030371A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473426B2 (en) * 2001-02-27 2009-01-06 Yun Seok Choe Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract
US20110027348A1 (en) * 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
ES2675942T3 (es) 2007-09-27 2018-07-13 Biothera, Inc. Tratamiento con B-glucano de síntomas de infección del tracto respiratorio superior y del bienestar psicológico
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US9034314B2 (en) 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
EP2401925B1 (fr) 2010-06-29 2014-05-07 Rosebud AG Produit prebiotique et procede de fabrication
US8673324B2 (en) 2012-01-19 2014-03-18 Industrial Technology Research Institute Method for producing gamma-aminobutyric acid and food produced thereby
US11135181B2 (en) * 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US10092609B2 (en) * 2015-01-16 2018-10-09 James A. Wieser Process for preparing medicinal mycological preparations

Also Published As

Publication number Publication date
US20200179469A1 (en) 2020-06-11
WO2019030371A1 (fr) 2019-02-14
EP3664894B1 (fr) 2021-09-29
PT3664894T (pt) 2021-12-17
EP3664894A1 (fr) 2020-06-17
US11872257B2 (en) 2024-01-16
ES2900380T3 (es) 2022-03-16
CA3072544A1 (fr) 2019-02-14

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL275482A (en) Asketamine for the treatment of depression
IL273693A (en) Treatment of inflammatory disorders
IL278299B (en) Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
SI3506904T1 (sl) Zdravljenje demence
IL246721B (en) History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
IL269604A (en) Pentides for the treatment of autoimmune diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
LT3458067T (lt) Neurologinių sutrikimų gydymas
SG11201708198SA (en) Methods for the treatment of cardiovascular disorders
GB201614415D0 (en) Enzymes for the treatment of human enterometabolic dysfunction
PT3664894T (pt) Saccharomyces boulardii para o tratamento de perturbações do humor
GB201516418D0 (en) Treatment of acute inflammatory disorders
AU2017903789A0 (en) Treatment of Atopy
GB201602784D0 (en) New treatment of CFTR-related disorders
AU2016905227A0 (en) Treatment of iron disorders
GB201610906D0 (en) Treatment of cardiovascular disease
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders
GB201513344D0 (en) Methods for the treatment of Cardiovascular disorders
GB201507109D0 (en) Methods for the treatment of cardiovascular disorders
SG10201913141UA (en) Treatment of alphavirus-induced inflammation